Case number 2017-2134
Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jan 11, 2019 | 6 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [577644] [17-2078, 17-2134] [PBC] [Entered: 01/11/2019 12:27 PM] (2) |
| Sep 10, 2018 | 5 | OPINION and JUDGMENT filed. The judgment or decision is: Affirmed, Cross-Appeal dismissed as moot. (Precedential Opinion). (For the Court: Newman, Circuit Judge; Dyk, Circuit Judge and Taranto, Circuit Judge). Dissenting opinion filed by Circuit Judge Newman. [548330] [17-2078, 17-2134] [SJ] [Entered: 09/10/2018 10:10 AM] (84) |
| Apr 6, 2018 | 3 | Letter from Cross-Appellants Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. Letter from lead counsel for Defendants-Appellees and Cross-Appellants Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. clearing the conflict for the Court's June oral argument session.. Service: 04/06/2018 by email. [511269] [17-2134] [Reid Smith] [Entered: 04/06/2018 12:16 PM] (0) |
| Apr 6, 2018 | 4 | NOTICE OF DEFICIENCY: The party letter Document No. [3] filed by Cross-Appellants Teva Pharmaceuticals USA, Inc. and Roxane Laboratories, Inc. in 17-2134 is not submitted in the lead appeal (17-2078) and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [511276] [JAB] [Entered: 04/06/2018 12:27 PM] (0) |
| Jun 7, 2017 | 1 | Appeal docketed. Received: 06/06/2017. [437130] [MJL] [Entered: 06/07/2017 01:43 PM] (135) |
| Jun 7, 2017 | 2 | Note to file: The following cases are consolidated: 17-2078 (Lead) with 17-2134 (Cross-Appeal). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [437158] [17-2078, 17-2134] [MJL] [Entered: 06/07/2017 02:01 PM] (0) |
